RAPT Therapeutics (RAPT) Revenue & Revenue Breakdown
RAPT Therapeutics Revenue Highlights
RAPT Therapeutics Revenue by Period
RAPT Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | -100.00% |
| 2022-12-31 | $1.53M | -59.95% |
| 2021-12-31 | $3.81M | -24.38% |
| 2020-12-31 | $5.04M | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2017-12-31 | - | - |
RAPT Therapeutics generated - in revenue during NA 2023, up -100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
RAPT Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $5.29M | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | -100.00% |
| 2022-12-31 | $641.00K | 100.00% |
| 2022-09-30 | - | -100.00% |
| 2022-06-30 | $886.00K | 38.22% |
| 2022-03-31 | $641.00K | -15.21% |
| 2021-12-31 | $756.00K | -21.74% |
| 2021-09-30 | $966.00K | 11.16% |
| 2021-06-30 | $869.00K | -28.89% |
| 2021-03-31 | $1.22M | -6.14% |
| 2020-12-31 | $1.30M | -14.79% |
| 2020-09-30 | $1.53M | 19.66% |
| 2020-06-30 | $1.28M | 36.58% |
| 2020-03-31 | $935.00K | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | - |
RAPT Therapeutics generated - in revenue during Q2 2024, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
RAPT Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ARVN | Arvinas | $78.50M | $76.50M |
| RLAY | Relay Therapeutics | $25.55M | - |
| HOWL | Werewolf Therapeutics | $19.94M | $742.00K |
| IKNA | Ikena Oncology | $9.16M | - |
| STOK | Stoke Therapeutics | $8.78M | $4.22M |
| MOLN | Molecular Partners | $7.04M | $2.74M |
| HCWB | HCW Biologics | $2.84M | $618.85K |
| PLRX | Pliant Therapeutics | $1.58M | - |
| ANEB | Anebulo Pharmaceuticals | - | - |
| DSGN | Design Therapeutics | - | - |
| RAPT | RAPT Therapeutics | - | - |
| BDTX | Black Diamond Therapeutics | - | - |
| ANTX | AN2 Therapeutics | - | - |
| PHVS | Pharvaris | - | - |
| CNTB | Connect Biopharma | - | - |
| ELYM | Eliem Therapeutics | - | - |
| PMVP | PMV Pharmaceuticals | - | - |
| MLYS | Mineralys Therapeutics | - | - |
| GLUE | Monte Rosa Therapeutics | - | $4.70M |
| PEPG | PepGen | - | - |
| TYRA | Tyra Biosciences | - | - |
| XLO | Xilio Therapeutics | - | $2.36M |
RAPT Revenue FAQ
What is RAPT Therapeutics’s yearly revenue?
RAPT Therapeutics's yearly revenue for 2023 was $0, representing a decrease of -100.00% compared to 2022. The company's yearly revenue for 2022 was $1.53M, representing a decrease of -59.95% compared to 2021. RAPT's yearly revenue for 2021 was $3.81M, representing a decrease of -24.38% compared to 2020.
What is RAPT Therapeutics’s quarterly revenue?
RAPT Therapeutics's quarterly revenue for Q2 2024 was $0, a 100.00% increase from the previous quarter (Q1 2024), and a 0% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023). RAPT's quarterly revenue for Q4 2023 was $5.29M, a 100.00% increase from the previous quarter (Q3 2023), and a 724.96% increase year-over-year (Q4 2022).
What is RAPT Therapeutics’s revenue growth rate?
RAPT Therapeutics's revenue growth rate for the last 3 years (2021-2023) was -100.00%, and for the last 5 years (2019-2023) was 0%.